AMP News

If you have special news to share, please email Dr. Wang (email: gwang@unmc.edu).

2025

Nov 26, 2025: lipid nanoparticle delivered AMP coding mRNA to combat lung infection.

Aug 6, 2025: TMcins is a new type of transmembrane helix-containing AMP (bacteriocin) that forms a large pore in membranes.

June 4, 2025: New family of antibiotics derived from the body's own proteins. AMPs, hidden in known protein sequences (i.e., encrpted AMPs), may be released to help combat infection in vivo and developed into new antibiotics.

May 15, 2025: How bacteria fight back against promising antimicrobial peptide. Note that TAT-RasGAP317-326 (see AP2980 in the APD) is a designed hybrid peptide which differs from natual membrane-targting peptides. According to the APD6, peptides that developed resistance tend to have lower hydrophobic ratio.

Feb 3, 2025: Generative AI pipeline creates promising antimicrobial peptides for screening.

2024

Aug 01, 2024: dmSLAY library screening: the closer to natural AMPs, the better

July 03, 2024: AMP mixtures: too many bullets to dodge for resistant pathogens

June 11, 2024: Cyclic peptides to fight AMR

June 05, 2024: AI predction: largest-ever antimicrobial sequence discovery from biosphere

May 02, 2024: Cow AMPs can treat incurable bacteria infection

2023

Dec 22, 2023: Scorpion venom peptides inhibit SARS-CoV-2 at IC50 of 200 nM. See AP03940

July 2023: Human cathelicidin LL-37 can facilitate the delivery of specific and efficient CRISPR/Cas9 system targeting HPV16 oncogenes

May 2023: Novel Polymyxin-Inspired Peptidomimetics Targeting the SARS-CoV-2 Spike:hACE2 Interface

2022

Nov 15, 2022: In silico identification of SARS-Cov-2 peptide inhibitors

Oct 22, 2022: Vitamin D enhances type I IFN signaling in COVID-19 patients

April 25, 2022: Improved database filtering technology succeeded in designing ab initio antiviral peptides against Zika viruses and SARS-Cov-2

2021

June 26, 2021: Human defensins HNPs1-3, HD5, and a theta-defensin RC101 inhibit SARS-COV2 via blocking viral entry

June 11, 2021: Human cathelicidin LL-37 inhibit SARS-COV2 by binding to the receptor-binding domain of S1 (11.2 nM), thereby decreasing the recruitment of ACE2

2020

May 28, 2020: Vitamin D deficiency and air pollution worsen COVID-19 due to suppressing LL-37

May 11, 2020: Expression of LL-37 to treat COVID-19 patients (Not reviewed manuscript)

April 1, 2020: Lectin-like Intestinal Defensin HD5 Inhibits 2019-nCoV (SARS-CoV2) Spike binding to the ACE2 receptor (unreviewed report)

March 22, 2020: Engineered human cathelicidin LL-37 peptides inhibit Ebola virus infection

March 3, 2020: Opossum Cathelicidins Exhibit Activity Against West Nile Virus

Jun 17, 2019: Low cationicity is important for systemic in vivo efficacy of database designed peptides against MRSA

Jan 10, 2018: A new gel against deadly, drug-resistant superbugs

Jan 10, 2018: LL-37 inhibits Zika virus

April 21, 2017: Frog Urumin against influenza A virus H1N1

April 17, 2017: Potential Antibiotic from a Dragon's Blood

April 3, 2017: Strategy to enhance activity

Nov. 4, 2016: New AMP kills resistant strains

Sept 22, 2016: Plant AMPs Targets Dental Plaque and Gum Tissues

Jan 5, 2015: Fat Isn't All Bad

Nov 2009: RTD-1 prevents mouse death infected with SARS-CoV

Nov 2007: Human cathelicidin LL-37 inhibits HIV-1

Created April 2017; updated and formatted: Jan 2026 | APD Copyright 2003-present Dept of Pathology, Microbiology and Immunology, UNMC All Rights Reserved